Nisa Investment Advisors LLC Takes Position in Ionis Pharmaceuticals Inc (IONS)

Nisa Investment Advisors LLC purchased a new position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,359 shares of the company’s stock, valued at approximately $380,000.

A number of other large investors also recently bought and sold shares of IONS. Dimensional Fund Advisors LP grew its holdings in Ionis Pharmaceuticals by 5.7% in the first quarter. Dimensional Fund Advisors LP now owns 237,581 shares of the company’s stock worth $10,473,000 after purchasing an additional 12,770 shares during the period. Principal Financial Group Inc. grew its holdings in Ionis Pharmaceuticals by 4.0% in the first quarter. Principal Financial Group Inc. now owns 38,277 shares of the company’s stock worth $1,687,000 after purchasing an additional 1,479 shares during the period. Guggenheim Capital LLC grew its holdings in Ionis Pharmaceuticals by 2.1% in the first quarter. Guggenheim Capital LLC now owns 91,282 shares of the company’s stock worth $4,024,000 after purchasing an additional 1,893 shares during the period. Millennium Management LLC grew its holdings in Ionis Pharmaceuticals by 39.3% in the first quarter. Millennium Management LLC now owns 272,837 shares of the company’s stock worth $12,027,000 after purchasing an additional 76,920 shares during the period. Finally, Legal & General Group Plc grew its holdings in Ionis Pharmaceuticals by 2.9% in the first quarter. Legal & General Group Plc now owns 68,452 shares of the company’s stock worth $3,017,000 after purchasing an additional 1,925 shares during the period. Institutional investors and hedge funds own 85.59% of the company’s stock.

In related news, COO Brett P. Monia sold 16,493 shares of the business’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $54.00, for a total transaction of $890,622.00. Following the transaction, the chief operating officer now directly owns 24,834 shares in the company, valued at $1,341,036. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP C Frank Bennett sold 12,500 shares of the business’s stock in a transaction dated Wednesday, August 8th. The stock was sold at an average price of $45.00, for a total transaction of $562,500.00. Following the transaction, the senior vice president now owns 19,409 shares in the company, valued at $873,405. The disclosure for this sale can be found here. 2.44% of the stock is owned by company insiders.

A number of equities research analysts have commented on the stock. Morgan Stanley set a $45.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, October 3rd. Stifel Nicolaus raised their price target on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a “hold” rating in a report on Tuesday, September 25th. Piper Jaffray Companies set a $50.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, September 24th. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, September 17th. Finally, Zacks Investment Research cut shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 9th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $53.86.

Shares of NASDAQ IONS opened at $49.55 on Thursday. The stock has a market cap of $6.56 billion, a PE ratio of 619.38 and a beta of 2.44. Ionis Pharmaceuticals Inc has a 1 year low of $39.07 and a 1 year high of $59.62. The company has a quick ratio of 8.34, a current ratio of 8.38 and a debt-to-equity ratio of 0.76.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.20). The business had revenue of $117.75 million for the quarter, compared to analyst estimates of $128.22 million. Ionis Pharmaceuticals had a negative net margin of 7.20% and a negative return on equity of 1.22%. As a group, research analysts anticipate that Ionis Pharmaceuticals Inc will post -0.15 EPS for the current fiscal year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Recommended Story: How do investors use RSI to grade stocks?

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply